On Thursday, the total number of confirmed cases of COVID-19 in the U.S. that had been reported to the Centers for Disease Control (CDC) swelled to 100 -- and next week, that number is probably going to climb much further. That's because the country's second-largest provider of clinical testing services, Quest Diagnostics (NYSE:DGX), has announced plans to begin helping the CDC unwind its backlog of coronavirus tests.

During January and February, U.S. healthcare officials isolated some people at risk of carrying SARS-CoV-2, the virus that causes COVID-19. Unfortunately, a shortage of fully approved testing kits means that it's still unclear how many infected individuals may have slipped through the cracks. It's fairly likely to be a large number. In the past two months, just a few thousand people with suspected cases of COVID-19 were actually tested in the U.S.

Coronavirus blood vial

Image source: Getty Images.

The Food and Drug Administration allows providers of healthcare and other services to use their own laboratory-developed tests (LDTs) with relatively little oversight. But to avoid potential calamities, the FDA requires companies like Quest Diagnostics to run every test they plan to market through a series of regulatory hoops first.

The FDA is making a highly unusual exception for Quest Diagnostics by allowing it to provide this service on a nationwide scale without subjecting its coronavirus test to the usual battery of tests. Quest's COVID-19 diagnostic will be an LDT, with the respiratory specimens collected at hospitals and doctors' offices -- not at Quest locations, and not by its employees.

Manic Monday

One out of three American adults has a medical test done by Quest Diagnostics annually, so once the company gets this service firing on all cylinders, relatively rapid testing for COVID-19 should become the new normal. The company says it will be ready to receive specimens and begin testing on Monday.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.